ESMO 2019

Breast Cancer

Triple negative breast cancer gets positive news: KEYNOTE-522 interim results

Presented By

Prof. Peter Schmid, Queen Mary University of London, UK

Trial

Phase 3, KEYNOTE-522

Conference

ESMO 2019

26 November, 2019 23:12

CDK4/6 inhibitors change landscape of breast cancer treatment: 2 studies

Presented By

Prof. Dennis Slamon, Prof. George Sledge, Prof. Nadia Harbeck

Trial

Monaleesa-3, Monarch 2

Conference

ESMO 2019

26 November, 2019 22:03

Veliparib-chemo combo prolongs survival without disease progression in some advanced breast cancer patients

Presented By

Veronique Diéras, Centre Eugène Marquis, Rennes, France

Trial

Phase 3, BROCADE 3

Conference

ESMO 2019

26 November, 2019 14:04

Lung Cancer

Melanoma

Long-term data from CheckMate 067

Presented By

Prof. James Larkin, Royal Marsden NHS Foundation Trust, London, UK

Trial

Phase 3, CheckMate 067

Conference

ESMO 2019

26 November, 2019 23:06

Adjuvant nivolumab provides benefit

Presented By

Prof. Jeffrey S. Weber, NYU Langone Medical Center, New York City, USA

Trial

Phase 3, CheckMate 238

Conference

ESMO 2019

26 November, 2019 22:15

Nivolumab+ipilimumab superior to monotherapy for melanoma brain metastases

Presented By

Prof. Georgina Long, Melanoma Institute Australia, Sydney, Australia

Trial

ABC

Conference

ESMO 2019

26 November, 2019 14:15

GI Cancers

Preoperative chemotherapy for colon cancer

Presented By

Prof. Dion Morton, University of Birmingham, UK

Trial

FOxTROT, phase 2/3

Conference

ESMO 2019

26 November, 2019 23:20

Nivolumab improves OS in advanced oesophageal cancer

Presented By

Prof. Byoung Chul Cho, Yonsei University College of Medicine, South Korea

Trial

Phase 3, ATTRACTION-3

Conference

ESMO 2019

26 November, 2019 22:19

Liquid biopsy identifies relapse in patients with colorectal cancer after surgery

Presented By

Prof. Julien Taieb, Hopital European Georges Pompidou, France

Trial

Phase 3, IDEA-FRANCE

Conference

ESMO 2019

26 November, 2019 21:17

In hepatocellular carcinoma, CheckMate 459 misses OS endpoint, but some interesting trends emerge

Presented By

Dr Thomas Yau, University of Hong Kong, China

Trial

Phase 3, CheckMate 459

Conference

ESMO 2019

26 November, 2019 20:21

Heavily pre-treated GIST: ripretinib improves PFS

Presented By

Prof. Margaret von Mehren, Fox Chase Cancer Center, USA

Trial

Phase 3, INVICTUS

Conference

ESMO 2019

26 November, 2019 19:21

FGFR2+ cholangiocarcinoma: pemigatinib active as second-line treatment

Presented By

Prof. Antoine Hollebecque, Gustave Roussy Cancer Center, France

Trial

Phase 2, FIGHT-202

Conference

ESMO 2019

26 November, 2019 18:21

IDH1+ cholangiocarcinoma: phase 3 results show improved PFS

Presented By

Dr Ghassan Abou-Alfa, Memorial Sloan-Kettering Cancer Center, New York, USA

Trial

Phase 3, ClarIDHy

Conference

ESMO 2019

26 November, 2019 17:22

Advanced colorectal cancer and BRAF mutations: triplet combination improves survival

Presented By

Prof. Scott Kopetz, MD Anderson Cancer Center, Houston, USA

Trial

Phase 3, BEACON CRC

Conference

ESMO 2019

26 November, 2019 14:22

Genitourinary Cancers

Gynaecological Cancers

Ovarian cancer patients benefit from combined maintenance therapy

Presented By

Prof. Isabelle Ray-Coquard, Université Claude Bernard, Lyon, France

Trial

Phase 3, PAOLA-1/ENGOT-ov25

Conference

ESMO 2019

26 November, 2019 23:25

Combination of PARP inhibition plus chemotherapy in ovarian cancer

Presented By

Robert Coleman, University of Texas, MD Anderson Cancer Center, Houston, USA

Trial

Phase 3, VELIA

Conference

ESMO 2019

26 November, 2019 22:26

PFS benefit with niraparib as first-line maintenance in ovarian cancer

Principal Investigator

Prof. Antonio González Martín, Clinica Universidad de Navarra, Spain

Trial

Phase 3, PRIMA/ENGOT-OV26/GOG-3012

Conference

ESMO 2019

26 November, 2019 14:26

CNS Tumours

Solid Tumours/Pan-Tumour Data

Mixed data: AMG 510 in tumours with KRASG12C

Presented By

Prof. Ramaswamy Govindan, Washington University, St Louis, USA

Conference

ESMO 2019

26 November, 2019 23:30

DNA profiling of carcinoma of unknown primary should inform treatment

Presented By

Prof. Karim Fizazi, University of Paris Sud, France

Trial

GEFCAPI 04, CUPISCO

Conference

ESMO 2019

26 November, 2019 22:30

Larotrectinib: safe and effective in TRK fusion-positive tumours

Presented By

Dr David Hyman, Memorial Sloan Kettering Cancer Center, New York, USA

Trial

SCOUT, NAVIGATE

Conference

ESMO 2019

26 November, 2019 14:30